Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending January 11, 2007. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically regarding changes in beneficial interests in the company's Ordinary Shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of a specific share transaction rather than a financial performance report.
Material Changes
The only material change disclosed is the acquisition of a beneficial interest by Mr. R Bondy. He purchased 2 Ordinary Shares under a Personal Equity Plan on January 9, 2007, at a price of GBP 13.61 per share. The company and the individual were advised of this transaction on January 10, 2007.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, risk factors, contingencies, or unusual items. It strictly adheres to Disclosure Rule 3.1.4R(1)(a) regarding the notification of the director's share transaction.
Investor Verification Points
- Verify the identity of Mr. R Bondy as a director or person discharging managerial responsibility.
- Confirm the transaction date (January 9, 2007) and price (GBP 13.61) against market data for that period.
- Note that this filing does not reflect the company's overall financial health or operational results.